TAKE Solutions Ltd., a technology firm focused on life sciences, is targeting a 25 per cent annual growth taking advantage of the developments in biotech sector.
“Demand environment is positive as more and more drugs are being brought to the market, especially with regard to biotech and bio-similars, both fast-growing categories. In 2004, out of top 10 selling drugs in the world, only one was biologic, while the remaining were chemical compounds.
“In 2015, out of the top 10, six were biologics. There is a clear migration towards biotech sector. There is a tremendous opportunity for us,” H. R. Srinivasan,Vice Chairman and Managing Director, Take Solutions told The Hindu.
The optimism for such growth prospects comes from growing demand for solutions, change in regulations in top markets and growing complexity in clinical trials in the life sciences segment. (Biologics are genetically-engineered proteins derived from human genes, while bio-similars are biologic medical products whose active drug substance is made by a living organism or is derived from one.) For the half-year ended December 2015, consolidated net sales of the company grew by 39 per cent to Rs 718.07 crore compared to the year-ago period.
“We offer process and strategic consultancy, bringing in technology solutions through our own IP to solve business problems and also help in the client’s migration process to develop a pipeline of products,” said Ram Yeleswarapu, President, TAKE Solutions.
The company is now eyeing acquisitions to support its growth plans.
